Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Krsnaa Diagnostics's Debt-to-EBITDA or its related term are showing as below:
NSE:KRSNAA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.69 Med: 0.47 Max: 2.09
Current: 2.02
During the past 8 years, the highest Debt-to-EBITDA Ratio of Krsnaa Diagnostics was 2.09. The lowest was -4.69. And the median was 0.47.
NSE:KRSNAA's Debt-to-EBITDA is ranked better than 54.39% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.385
vs NSE:KRSNAA: 2.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Krsnaa Diagnostics Debt-to-EBITDA Related Terms
Krsnaa Diagnostics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Krsnaa Diagnostics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:KRSNAA vs TMO, DHR, NTRA: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Krsnaa Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krsnaa Diagnostics Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Krsnaa Diagnostics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Krsnaa Diagnostics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Krsnaa Diagnostics (NSE:KRSNAA) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Krsnaa Diagnostics. According to the industry distribution chart, Krsnaa Diagnostics ranks #52 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 45.6%.
Is Krsnaa Diagnostics' Debt-to-EBITDA too high?
Krsnaa Diagnostics' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Krsnaa Diagnostics ranks #52 out of 114 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Krsnaa Diagnostics has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Krsnaa Diagnostics' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Krsnaa Diagnostics ranks #52 out of 114 companies for Debt-to-EBITDA. This puts Krsnaa Diagnostics in the upper half of its industry. The industry median Debt-to-EBITDA is 2.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.39, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Krsnaa Diagnostics. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krsnaa Diagnostics's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krsnaa Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Krsnaa Diagnostics (NSE:KRSNAA) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹910.84, compared to a current price of ₹564.05 — trading 38.1% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Krsnaa Diagnostics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Krsnaa Diagnostics (NSE:KRSNAA), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krsnaa Diagnostics (NSE:KRSNAA) Overvalued in 2026?
Based on GuruFocus' analysis, Krsnaa Diagnostics stock appears to be undervalued.
The current stock price of ₹564.05 is trading 38.1% below its estimated GF Value™ of ₹910.84.
GuruFocus considers Krsnaa Diagnostics to be Significantly Undervalued.
Key valuation signals for NSE:KRSNAA:
Debt-to-EBITDA: 0.00
GF Value™: ₹910.84 vs. price of ₹564.05 (38.1% below fair value)
No single metric tells the full story. See the NSE:KRSNAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krsnaa Diagnostics Ltd is a diagnostic services provider, both in Radiology and Pathology. It offers a wide range of diagnostic services such as imaging/radiology services, routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres. The company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, tele-reporting services, and all types of Blood and Urine investigations.
71GF Score
Get the complete analysis for NSE:KRSNAA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KRSNAA has been successfully added to your 
